Aristides Capital’s Cytosorbents Corp CTSO Stock Holding History

Aristides Capital’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,762	Closed	-$66K	–	213
2021 Q4	$66K	Buy	+15,762	New	+$88.4K	0.03%	255

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Aristides Capital's CTSO Position: Q1 2022 in Review

Aristides Capital sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 15,762 shares — an estimated $66K sold.

Aristides Capital first reported a position in CTSO in Q4 2021 and held it in 1 quarter. The position peaked at $66K in Q4 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

Aristides Capital reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
Aristides Capital sold 15,762 Cytosorbents Corp shares in Q1 2022, an estimated $66K.
Aristides Capital first reported a position in Cytosorbents Corp in Q4 2021 and held it in 1 quarter.
Aristides Capital's Cytosorbents Corp position peaked at $66K in Q4 2021.
88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.